# Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

> **NCT00038311** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 120 (—)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** PN-152,243)/PN-196,444

## Key facts

- **NCT ID:** NCT00038311
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-09
- **Primary completion:** —
- **Final completion:** 2003-03
- **Target enrollment:** 120 (—)
- **Last updated:** 2015-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038311, "Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00038311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*